A new spray-based treatment for allergic respiratory diseases has been developed, offering an alternative to traditional injection therapies.
The research team, led by Professor Kim Joo-young of Yonsei University College of Medicine, Professor Cho Hyung-joo of Severance Hospital, and Professor Park Joon-sang of Hongik University, announced the creation of a nano-sized antibody drug designed to treat chronic rhinosinusitis by directly targeting nasal inflammation.
Unlike conventional treatments such as oral medications and injections, this new therapy uses nanobodies—tiny proteins approximately 2-4 nanometers in size—that are sprayed directly onto the inflamed nasal surface, significantly improving treatment efficacy while minimizing discomfort for patients.
The nanobodies specifically target the IL-4Rα receptor, a protein involved in immune response and inflammation regulation.
Published in the international journal Materials Today Bio, the study shows that this spray-based treatment not only enhances drug penetration at the site of inflammation but also reduces the risk of side effects associated with long-term oral steroid use and antibody injections.
Professor Cho Hyung-joo explained, “This new spray treatment addresses the limitations of current therapies, including side effects, high costs, and patient discomfort, and is expected to significantly aid in the treatment of chronic rhinosinusitis and other allergic respiratory diseases.”
This research was supported by the Korea Research Foundation’s Convergence Basic Research Laboratory project.
Editor 메디마스터
Provided by: YONSEI UNIVERSITY HEALTH SYSTEM
유방암 난소암 가족력? 유전자 검사로 대비하세요. 분당차여성병원이 난소암 및 유방암 가족력이 있는 경우 BRCA(브라카) 유전자…
유년기 아이들 생선 섭취, 이타적 행동과 협력심에 긍정적 영향 — 오메가-3·요오드, 아동 친사회성에도 긍정적 작용…
대웅제약·고대 안암병원, 정밀의료 협력으로 신약개발 혁신 대웅제약(대표 박성수·이창재)은 고려대학교 안암병원 연구부(연구부원장 박범진)와 인공지능(AI)을 활용한 신약…